Skip to main content

Increasing prevalence of cancer is supporting the growth of the global recombinant human endostatin market

 


North America is expected to lead the global recombinant human endostatin market and this is attributed to the high prevalence of cancer in the region which is creating demand for such therapy. According to a report by the Centers for Disease Control and Prevention (CDC), around 1,633,390 new cancer cases were reported in the U.S. in 2015 and the number is expected to reach 1,735,350 in 2018. Also, an increasing number of clinical trials is again expected to foster the growth of the market.

Key players operating in the global recombinant human endostatin market include Pfizer Inc., Novus Biologicals, Biocon, Thermo Fisher Scientific, Yantai Medgenn Ltd., FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd., PeproTech, Inc., Onyx Pharmaceuticals, Inc., Genexine, Inc., Hetero., Intas Pharmaceuticals Ltd., and Novartis AG.

A growing number of research & development activities to recognize potential applications of recombinant human endostatin is expected to foster the growth of the recombinant human endostatin market. Increasing demand for cancer treatment and ongoing studies to identify potential collagen are again fostering the growth of the market. According to the World Health Organization (WHO), around 18.1 million new cases of cancer were recorded in 2018, with 9.6 million deaths due to the disease. Also, the rise in the geriatric population around the globe coupled with the expanding pharmaceutical & biotechnology companies using recombinant human endostatin is further projected to foster the growth of the market.

Moreover, increasing investment in the research &development activities based on the use of recombinant technology is further anticipated to augment the growth of the market.

In January 2017, the PLA General Hospital in China has undertaken a clinical phase II study for recombinant human endostatin combination with radiotherapy for the treatment of Hepatocellular Carcinoma (HCC). The study was estimated to complete in December 2019.

A clinical trial is a rigorous medical procedure intended to test an important new medical product or procedure. The goal of such a trial is to provide evidence for or against the effectiveness, safety, and effectiveness of medical treatment. Clinical trials are conducted by healthcare companies to test drugs, medical devices, and other health products. Sometimes, healthcare companies conduct both clinical trials and consumer-based tests to determine whether a new product's benefits are worth the cost of introducing it into the marketplace. For Recombinant Human Endostatin, a biotechnology company called Generex has conducted an important clinical trial.

 

Labels:

Comments

Post a Comment

Popular posts from this blog

The Global Pressure Bandages Market Is Witnessing High Growth Owing To the Increasing Incidence of Surgical Processes in the World

  Market Overview: During a medical emergency, a pressure bandage is used to apply pressure to an area of the body to control bleeding and swelling. There are a variety of types of pressure bandages that can be used for different purposes. The bandage is made up of several parts, including an air bladder, a pad, a closure bar, and an applicator. A pressure bandage can be applied to wounds at any location on the body. This type of dressing is useful in treating various conditions, including gunshot wounds. It can also be used for a temporary holding of a hernia. The bandage is usually vacuum-sealed, so it's easier to carry. Competitive Landscape: Major players operating in the global pressure bandages market include ConvaTec Group PLC., Cardinal Health, 3M, B. Braun Melsungen AG, Lohmann & Rauscher GmbH & Co. KG, Mölnlycke Health Care AB, Smith & Nephew plc., Paul Hartmann AG, and Essity (BSN medical GmbH). Key Market Drivers: Increasing developments by key pla...
Post a Comment
Read more

Biologics Market Increasing Prevalence of Chronic Diseases to Augment Growth of the market

  A  biologic  drug ( biologics ) is a product that is produced from living organisms or contains components of living organisms.  Biologic  drugs are widely used to prevent, diagnose, treat, or cure a variety of diseases, including infectious diseases, autoimmune disorders, chronic kidney disease, and cancer. Market Dynamics In the recent past, several novel biopharmaceutical products were approved by major regulatory bodies and major players in the market have launched various novel and innovative biopharmaceutical products. Rapid approvals and launches of novel products in the market are expected to be major drivers for growth of the biologicsmarket . 
Post a Comment
Read more

Custom Antibody Service Market Segmentation Application, Technology and Market Analysis to 2028

  The immune system produces antibodies in response to pathogen invasion. Antigens are the collective term for the invasive bacteria, viruses, or other foreign molecules. Antibodies are proteins, or polypeptides which have specific antigen recognition sites. It is possible to have antibodies made using custom antibody production when an antibody is required against a particular antigen but it is not offered by a supplier. These antibodies can be either polyclonal or monoclonal, depending on how they are produced and harvested. Polyclonal  antibodies  are capable of recognizing multiple sites on an antigen. They are derived from different B-cell lineages. Monoclonal antibodies recognize only one epitope or site on an antigen, and are derived from a single B-cell line. Global custom antibody service market is estimated to be valued at  US$ 444.85 Million in 2022  and expected to reach  US$ 930.46 million by 2030 , witnessing a  CAGR of 9.7 %  over...
Post a Comment
Read more